| On more than one occasion over the past year, recommendations have been submitted to the regulatory authority responsible for pharmaceutical pricing in Hong Kong, proposing that medicines with existing approved indications be permitted to register new indications under a special licensing arrangement. | 移植
> 移植：肝臟 | 監管合作關係
> 與監管機構合作 | 5,000 | Regional | Regularly | 115046959426 |
| On more than one occasion over the past year, recommendations have been submitted to the regulatory authority responsible for pharmaceutical pricing in Hong Kong, proposing that medicines with existing approved indications be permitted to register new indications under a special licensing arrangement. | 移植
> 移植：肝臟 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | 5,000 | Regional | Regularly | 115046959426 |
| As an orphan medicinal product for a rare disease, the cost is prohibitively high. Strong representations to this effect have already been made to the Government, the HA [[醫院管理局 – Hospital Authority], and the relevant pharmaceutical manufacturers. | 稀有
> 罕見疾病：大多數類型 | 影響政策與立法
> 影響醫療保健政策與法規 | 100 | Regional | Rarely | 115017299676 |
| We suggested a big pharmaceutical company to reduce its selling price as it is not affordable by the patients. | 病患倡導
> 病患倡導 | 定價與可負擔性倡議
> 倡導公平的藥品定價 | 5,000 | Regional | Sometimes | 115004724749 |
| The dual-pricing fees are prohibitively high. | 未指定
> 未指定 | 定價與可負擔性倡議
> 倡導公平的藥品定價 | 1,000 | Regional | Sometimes | 115053340704 |
| We suggested a big pharmaceutical company to reduce its selling price as it is not affordable by the patients. | 病患倡導
> 病患倡導 | 定價與可負擔性倡議
> 要求製造商降低銷售價格 | 5,000 | Regional | Sometimes | 115004724749 |
| We suggested a big pharmaceutical company to reduce its selling price as it is not affordable by the patients. | 病患倡導
> 病患倡導 | 定價與可負擔性倡議
> 追蹤與監控藥品定價／藥品短缺 | 5,000 | Regional | Sometimes | 115004724749 |
| On more than one occasion over the past year, recommendations have been submitted to the regulatory authority responsible for pharmaceutical pricing in Hong Kong, proposing that medicines with existing approved indications be permitted to register new indications under a special licensing arrangement. | 移植
> 移植：肝臟 | 定價與可負擔性倡議
> 倡導將產品納入給付清單/國家藥品目錄 | 5,000 | Regional | Regularly | 115046959426 |
| We have addressed the issue of treatment options to the health authority. | 視覺障礙
> 視網膜疾病 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | 1,000 | Local | Sometimes | 119068473108 |
| The cost of rare disease medicines classified as orphan drugs is extremely high. | 稀有
> 罕見疾病：大多數類型 | 改善存取路徑
> 改善罕見/極罕見療法的取得管道 | 100 | Regional | Rarely | 115017299676 |
| As an orphan medicinal product for a rare disease, the cost is prohibitively high. Strong representations to this effect have already been made to the Government, the HA [[醫院管理局 – Hospital Authority], and the relevant pharmaceutical manufacturers. | 稀有
> 罕見疾病：大多數類型 | 改善存取路徑
> 改善罕見/極罕見療法的取得管道 | 100 | Regional | Rarely | 115017299676 |
| The pricing of so-called 'orphan drugs' — medications designated for the treatment of rare diseases — is prohibitively expensive. | 神經系統
> 神經纖維瘤病（NF） | 改善存取路徑
> 改善罕見/極罕見療法的取得管道 | 100 | Regional | Rarely | 115018622259 |
互動
行動與倡議
